Equities Research Analysts’ Updated EPS Estimates for August 18th (ACTU, AMRC, AMX, ANF, ANVS, APO, ARDX, ASMB, ATHM, BHP)

Equities Research Analysts’ updated eps estimates for Tuesday, August 18th:

Actuate Therapeutics (NASDAQ:ACTU) had its buy rating reaffirmed by analysts at HC Wainwright.

Ameresco (NYSE:AMRC) had its neutral rating reissued by analysts at Robert W. Baird. They currently have a $32.00 price target on the stock, down from their previous price target of $36.00.

America Movil (NYSE:AMX) was upgraded by analysts at JPMorgan Chase & Co. from a neutral rating to an overweight rating. The firm currently has $32.00 price target on the stock, up from their previous price target of $30.00.

Abercrombie & Fitch (NYSE:ANF) had its market perform rating reaffirmed by analysts at Raymond James Financial, Inc..

Annovis Bio (NYSE:ANVS) had its buy rating reissued by analysts at Canaccord Genuity Group Inc..

Apollo Global Management (NYSE:APO) was upgraded by analysts at Wall Street Zen from a strong sell rating to a hold rating.

Ardelyx (NASDAQ:ARDX) had its outperform rating reiterated by analysts at Wedbush. Wedbush currently has a $9.00 price target on the stock.

Assembly Biosciences (NASDAQ:ASMB) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $50.00 target price on the stock.

Autohome (NYSE:ATHM) was downgraded by analysts at Bank of America Corporation from a neutral rating to an underperform rating. The firm currently has $19.00 target price on the stock.

BHP Group (LON:BHP) had its hold rating reaffirmed by analysts at Jefferies Financial Group Inc.. Jefferies Financial Group Inc. currently has a GBX 3,350 target price on the stock.

Webull (NASDAQ:BULL) had its buy rating reissued by analysts at Rosenblatt Securities. They currently have a $13.00 price target on the stock.

Americold Realty Trust (NYSE:COLD) was upgraded by analysts at Bank of America Corporation from an underperform rating to a neutral rating. The firm currently has $16.00 target price on the stock, up from their previous target price of $15.00.

DocGo (NASDAQ:DCGO) had its hold rating reaffirmed by analysts at Canaccord Genuity Group Inc.. Canaccord Genuity Group Inc. currently has a $1.00 price target on the stock.

DocGo (NASDAQ:DCGO) had its buy rating reiterated by analysts at Needham & Company LLC. They currently have a $3.00 price target on the stock.

Docusign (NASDAQ:DOCU) had its market outperform rating reiterated by analysts at Citizens Jmp. The firm currently has a $86.00 price target on the stock.

Domino’s Pizza Group (LON:DOM) had its outperform rating reissued by analysts at Royal Bank Of Canada. They currently have a GBX 230 price target on the stock.

Duolingo (NASDAQ:DUOL) was upgraded by analysts at DA Davidson from a neutral rating to a buy rating. The firm currently has $160.00 target price on the stock, up from their previous target price of $130.00.

Elicio Therapeutics (NASDAQ:ELTX) had its buy rating reiterated by analysts at HC Wainwright.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) had its neutral rating reiterated by analysts at HC Wainwright.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) had its sector perform rating reissued by analysts at Royal Bank Of Canada. The firm currently has a $5.00 target price on the stock.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) had its neutral rating reaffirmed by analysts at Chardan Capital. Chardan Capital currently has a $5.00 target price on the stock.

Fabrinet (NYSE:FN) had its buy rating reiterated by analysts at Rosenblatt Securities. The firm currently has a $750.00 price target on the stock.

Fabrinet (NYSE:FN) had its buy rating reaffirmed by analysts at Needham & Company LLC. Needham & Company LLC currently has a $650.00 price target on the stock.

Globalstar (NASDAQ:GSAT) was downgraded by analysts at Craig Hallum from a buy rating to a hold rating. They currently have $90.00 target price on the stock.

Huntington Bancshares (NASDAQ:HBAN) had its outperform rating reissued by analysts at Royal Bank Of Canada. Royal Bank Of Canada currently has a $21.00 price target on the stock.

Hermes International (OTCMKTS:HESAY) was downgraded by analysts at Royal Bank Of Canada from an outperform rating to a sector perform rating.

HIVE Digital Technologies (NASDAQ:HIVE) had its buy rating reaffirmed by analysts at Canaccord Genuity Group Inc.. Canaccord Genuity Group Inc. currently has a $10.00 price target on the stock.

TuHURA Biosciences (NASDAQ:HURA) had its market outperform rating reiterated by analysts at Citizens Jmp. The firm currently has a $9.00 price target on the stock.

Oncocyte (NASDAQ:IMDX) had its buy rating reaffirmed by analysts at Needham & Company LLC. They currently have a $9.00 price target on the stock.

LGN (NASDAQ:LGN) had its buy rating reiterated by analysts at Guggenheim. Guggenheim currently has a $115.00 target price on the stock.

Medtronic (NYSE:MDT) had its buy rating reaffirmed by analysts at BTIG Research. The firm currently has a $91.00 price target on the stock.

Ramaco Resources (NASDAQ:METC) had its neutral rating reaffirmed by analysts at Robert W. Baird. Robert W. Baird currently has a $13.00 target price on the stock.

Made Tech Group (LON:MTEC) had its buy rating reiterated by analysts at Canaccord Genuity Group Inc.. The firm currently has a GBX 60 price target on the stock.

Neo Energy Metals (LON:NEO) had its house stock rating reissued by analysts at Shore Capital Group Ltd.

NRx Pharmaceuticals (NASDAQ:NRXP) had its buy rating reiterated by analysts at BTIG Research. The firm currently has a $10.00 target price on the stock.

Oxford Biomedica (LON:OXB) was downgraded by analysts at Deutsche Bank Aktiengesellschaft to a hold rating. They currently have GBX 595 target price on the stock, down from their previous target price of GBX 800.

Perpetua Resources (NASDAQ:PPTA) had its buy rating reissued by analysts at HC Wainwright. HC Wainwright currently has a $43.50 target price on the stock.

Pyxis Oncology (NASDAQ:PYXS) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $7.00 target price on the stock.

Quince Therapeutics (NASDAQ:QNCX) had its overweight rating reissued by analysts at Cantor Fitzgerald. The firm currently has a $70.00 target price on the stock.

Cartesian Therapeutics (NASDAQ:RNAC) had its outperform rating reissued by analysts at Wedbush. Wedbush currently has a $38.00 target price on the stock.

Rein Therapeutics (NASDAQ:RNTX) had its buy rating reiterated by analysts at HC Wainwright.

Roper Technologies (NASDAQ:ROP) had its sector perform rating reissued by analysts at Royal Bank Of Canada. Royal Bank Of Canada currently has a $417.00 price target on the stock.

Summit Therapeutics (NASDAQ:SMMT) had its neutral rating reaffirmed by analysts at HC Wainwright.

Strawberry Fields REIT (NYSEAMERICAN:STRW) was upgraded by analysts at Compass Point from a neutral rating to a buy rating.

Millicom International Cellular (NASDAQ:TIGO) had its neutral rating reiterated by analysts at JPMorgan Chase & Co.. They currently have a $105.00 target price on the stock, up from their previous target price of $100.00.

Traws Pharma (NASDAQ:TRAW) had its neutral rating reissued by analysts at HC Wainwright. They currently have a $1.00 target price on the stock.

Tesla (NASDAQ:TSLA) had its sell rating reiterated by analysts at Glj Research.

TTM Technologies (NASDAQ:TTMI) had its buy rating reissued by analysts at Needham & Company LLC. The firm currently has a $220.00 price target on the stock.

Willdan Group (NASDAQ:WLDN) had its outperform rating reissued by analysts at Wedbush. The firm currently has a $130.00 target price on the stock.

Winvia Entertainment (LON:WVIA) had its house stock rating reissued by analysts at Shore Capital Group Ltd.